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Abstract
Transient leukemia (TL) is evident in 5–10% of all neonates with Down syndrome (DS) and
associated with N-terminal truncating GATA1-mutations (GATA1s). Here we report that TL cell
clones generate abundant eosinophils in a substantial fraction of patients. Sorted eosinophils from
patients with TL and eosinophilia carried the same GATA1s-mutation as sorted TL-blasts,
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tconsistent with their clonal origin. TL-blasts exhibited a genetic program characteristic of
eosinophils and differentiated along the eosinophil lineage in vitro. Similarly, ectopic expression
of Gata1s, but not Gata1, in wild-type CD34+-hematopoietic stem and progenitor cells induced
hyperproliferation of eosinophil promyelocytes in vitro. While GATA1s retained the function of
GATA1 to induce eosinophil genes by occupying their promoter regions, GATA1s was impaired
in its ability to repress oncogenic MYC and the pro-proliferative E2F transcription network. ChIP-
seq indicated reduced GATA1s occupancy at the MYC promoter. Knockdown of MYC, or the
obligate E2F-cooperation partner DP1, rescued the GATA1s-induced hyperproliferative
phenotype. In agreement, terminal eosinophil maturation was blocked in Gata1Δe2 knockin mice,
exclusively expressing Gata1s, leading to accumulation of eosinophil precursors in blood and bone
marrow. These data suggest a direct relationship between the N-terminal truncating mutations of
GATA1 and clonal eosinophilia in DS patients.
Keywords
Down syndrome; eosinophilia; GATA1s; MYC; E2F
Introduction
Children with Down syndrome (DS) have an increased risk of developing acute leukemia
(1;2). Approximately 10% of DS neonates present with transient leukemia (TL), which is
characterized by the accumulation of immature megakaryoblasts. TL resolves spontaneously
in the majority of cases (3). However, 20 to 30% of TL-patients progress to acute
megakaryoblastic leukemia (AMKL) (3–7).
Acquired mutations in exon 2/3 of the hematopoietic transcription factor GATA1 are
consistently present in DS-AMKL and TL (8). GATA1 is essential for the regulation of
differentiation, proliferation and apoptosis during erythropoiesis and megakaryopoiesis (9–
12). The exon 2/3 mutations in GATA1 that are associated with DS-AMKL and TL lead to
the expression of a shorter isoform (GATA1s), which lacks the N-terminal domain (8). We
previously showed that, compared to full-length GATA1, GATA1s fails to repress the E2F
transcription network due to impaired interaction with E2F proteins during fetal
megakaryocyte development (13). However, the molecular basis of impaired transcriptional
repression of transcription factors, including Gata2, Ikaros, Sfpi1 (encoding PU.1), Myb and
Myc, remained elusive (14–16).
GATA1 is essential not only for the formation of erythroid and megakaryocytic cells, but
also for proper development of eosinophils, basophils and mast cells (17–21). Normal
development of eosinophils is instructed by an interplay of the transcription factors GATA1,
GATA2, CEBPα and PU.1 (22). Promoter regions of numerous eosinophil-specific genes
encoding eosinophil granule proteins (PRG2 [eosinophil granule major basic protein], ECP
[eosinophil cationic protein; RNASE3], EDN [eosinophil-derived neurotoxin; RNASE2],
EPX [eosinophil peroxidase], CLC [Charcot-Leyden crystal protein]) and surface receptors
(IL-5Rα [interleukin-5 receptor alpha] and CCR3 [chemokine (C-C motif) receptor 3])
include known or putative GATA1 binding sites (22;23). Consistent with these findings,
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tenforced expression of Gata1 in committed mouse myelomonocytic progenitors converts
them into eosinophils, erythrocytes and basophil-like cells (24). Similarly, enforced
expression of GATA1 in human primary myeloid progenitors switches myelomonocytic to
an eosinophil fate (18). Therefore, GATA1 plays an instructive and essential role in
eosinophil development, which was proposed to be independent of its N-terminal domain
(18). TL and AMKL blasts contain basophil-like cytoplasmic granules (25) and differentiate
along the megakaryocytic lineage, but also along the basophil lineage (26;27).
Here we report differentiation of TL-blasts to the eosinophil lineage and show that
eosinophils are part of the TL cell clone. We provide a molecular link between GATA1s
expression and activation of eosinophil genes in TL-blasts, thereby accounting for the
accompanying eosinophilia.
Materials and Methods
Cell lines and patient samples
Human cell lines were obtained from the German Collection of Microorganisms and Cell
Cultures (DSMZ, Braunschweig, Germany). Culturing and maintenance were performed
according to the supplier's instructions. Patient samples were provided by the AML-'Berlin-
Frankfurt-Münster' Study Group (AML-BFM-SG, Hannover, Germany) and ‘The Hospital
for Sick Children’, Toronto. TL-blasts for in vitro studies were obtained from peripheral
blood of 4 TL-patients by ficoll-paque density centrifugation followed by sorting for
CD34+/CD41+/low blast population. Human CD34+-fetal liver cells were purchased from
Novogenic Laboratories, LLC (LA, USA). All investigations were performed in accordance
to the Declaration of Helsinki and informed consent was obtained according to local laws
and regulations.
Cell culture and lentiviral infection
TL-blasts were cultured as described (13;28). Differentiation was induced by myeloid
differentiation medium [RPMI, 20% FCS, 1% P/S, SCF (5ng/ml), GM-CSF (10ng/ml), G-
SCF (10ng/ml), IL-3 (5ng/ml)]. CD34+-cells were cultured, lentivirally transduced and
sorted on a FACSAria (BD, Heidelberg, Germany) as previously described (29).
Viral vectors and lentivirus production
cDNAs of either full length or short Gata1 were cloned into a modified LeGO-iG vector
(30), where the mU6 was replaced by the hU6 promoter. shRNA against human GATA1,
obtained from Open Biosystems (Schwerte, Germany) clone ID: TRCN0000019223), was
cloned downstream of the hU6 promoter. shRNA sequences for DP1 and MYC are available
upon request. For production of lentiviral supernatant, standard protocols were followed as
previously described (29;31).
High-throughput chip cytometry
Single colonies were picked from methylcellulose cultures, washed and resuspended in PBS
before applying to cell-adhesive microfluidic-chips. Chip cytometry (http://
www.chipcytometry.com) was performed on a Zeiss Axio Imager M2 automated
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tmicroscope using CellHopperX software as described (32). Raw data generalized Box-Cox
transformation and heat map production were performed with R package versions 1.8.0. for
BioConductor (32).
ChIP-Seq
Gene coding for biotinylation enzyme BirA has been introduced into human megakaryocytic
cell line CMK, in which only N-truncated GATA1s is endogenously expressed, by stable
transfection via electroporation (Amaxa Cell Line Nucleofector Kit C, Promega). Positive
clones were subsequently transduced by retroviral vector encoding BIO-tagged GATA1 or
GATA1s and cultured in the presence of 2 µg/ml puromycin and 4 µg/ml G418. Chromatin
immunoprecipitation (ChIP) was performed using streptavidin-bound Dynabeads
(Dynabeads MyOne Streptavidin T1; Invitrogen) as previously described (33;34). ChIP-seq
analysis was performed using the Illumina™ HiSeq2000. 10–20 ng of ChIP DNA was
processed for library generation using the ChIP-seq Sample Preparation Kit (Illumina, San
Diego, CA, USA) following the manufacturer’s protocol. Raw ChIP-seq data were
processed using the Illumina software pipeline and ChIP-seq reads aligned to exactly one
location in the reference human genome (UCSC, hg18) as previously described (34).
In vitro differentiation from mouse ESCs
Eosinophil in vitro differentiation from knockin murine embryonic stem cells (ESCs)
expressing the BirA enzyme (BirA) together with a biotinylated form of Gata1 (bioGata1) or
Gata1s (bioGata1s) from its endogenous locus (35) was adapted from a previously described
protocol (36). Briefly, 2.5 × 104 ESCs were seeded into a 10 cm dish containing an OP9 cell
layer and differentiated in α-MEM supplemented with 20% FBS (PAA, Yeovil Somerset;
UK). On day 5, ESC colonies were dissociated with 0.25% Trypsin, cells were incubated in
culture medium for 45 minutes at 37°C to let the OP9 cells attach to the dish and 106
suspension cells were transferred onto a fresh OP9 layer in a 10 cm dish. From day 7, IL3
(10 ng/mL) and IL5 (10 ng/mL) were added to the culture. On day 10 and 15, the cells in
suspension and slightly attached cells were harvested by vigorous pipetting and transferred
onto a fresh OP9 layer. On day 15, cells in suspension were transferred to a new dish
without OP9 cells. On day 20, cells were analyzed by FACS.
Mice
All studies involving mice were approved by the Hannover Medical School Institute for
laboratory animal science and local authorities and performed in accordance with the
relevant protocol. Blood counts were measured on the scil Vet abc blood counter (Horiba
Medical, Europe). Flow cytometry of total bone marrow and peripheral blood was
performed after red blood cell lysis (Pharm Lyse reagent; Becton Dickinson).
Statistical analysis
Statistical evaluation between the two groups was carried out using Student’s t-test and for
more than two groups by 1-way ANOVA with Duncan’s or Bonferroni’s post-hoc analysis.
The level of significance was set at P<0.05. Calculations were performed using GraphPad
Prism 5 (STATCON, Witzenhausen, Germany).
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A substantial proportion of TL patients have increased eosinophils in the peripheral blood
carrying the mutated GATA1s allele
Between June 1998 and August 2011, 70 DS neonates were diagnosed with TL by
morphological examination of blood smears in the central AML reference laboratory of the
AML-BFM study group. The median age at diagnosis was 6.5 days (range: 2 – 56d) and
GATA1s mutation was confirmed in 25/27 tested patients (93%). Interestingly, 11 patients
(16%) presented with an elevated (more than 600 ×106/L) absolute eosinophil count (AEC;
range: 820–8960 ×106/L, mean: 3655 ×106/L) or elevated (equal or more than 4%) relative
eosinophil count (REC; range: 4–53%, mean: 11.5%; median age: 31 days; range: 1–65d;
Figure 1a). Morphologically, most eosinophils in these patients appeared immature and
contained basophilic granules (Figure 1b). Leukemic blasts with eosinophilic and basophilic
granules were also seen (Figure 1b).
GATA1 is involved in eosinophil differentiation. Since TL and DS-AMKL blasts have
elevated levels of GATA1s (37), we sought to investigate whether immature eosinophils
were intrinsic to the leukemic clone or reflected a secondary reaction to the TL. We sorted
populations of blasts (CD34+/CD41+/low) and eosinophils (CD15+/CD52+/CD16−) from four
TL patients with eosinophilia (Supplementary Figure 1a–b). Efficiency of sorting was
confirmed by cytospins and qRT-PCR (Figure 1c and Supplementary Figure 1c).
Morphologically sorted CD15+/CD52+/CD16− cells constituted a mixture of eosinophil
myelocytes and metamyelocytes. Basophilic granules are characteristic for eosinophil
precursors and disappear during normal eosinophil differentiation (Supplementary Figure 2).
Sequencing of the GATA1 locus from the sorted populations revealed the same mutation in
the eosinophilic cells and megakaryoblasts (Figure 1c). Thus, the eosinophilic cells in TL
can originate from the preleukemic clone.
TL-blasts can differentiate into eosinophils in vitro
Next we performed gene set enrichment analysis (GSEA (38)) using previously published
gene-expression profiles of sorted megakaryoblasts from TL patients without documented
eosinophilia and non-DS-AMKL patients (13). This showed the enrichment of a set of
specific eosinophil genes (39) in TL-blasts as compared to non-DS-AMKL-blasts (Figure
2a). Thus, TL-blasts express a gene program characteristic of differentiated eosinophils.
To directly test whether TL-blasts can fulfill this intrinsic eosinophil program during
differentiation, we cultured sorted TL-blasts from three patients (for GATA1s status see
Supplementary Table 1) in medium containing G-CSF, GM-CSF, IL3 and SCF (40). Under
these culture conditions, normal CD34+-hematopoietic stem and progenitor cells (HSPCs)
differentiate into monocytes and granulocytes (Figure 2b and 3c–d) (41). Remarkably,
despite the lack of documented eosinophilia in these patients in vivo, TL-blasts of all three
patients differentiated into cells with densely granulated cytoplasm, resembling eosinophil
precursors (Figure 2b). Eosinophil genes (ECP, EPX, CLC and PRG2) were significantly
activated (Figure 2c). Expression of the basophil lineage gene HDC was only modestly
affected (Figure 2c). The majority of cells were negative for toluidine blue, which
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2d, see ‘positive control’). Thus, we propose that TL-blasts cannot only differentiate along
the megakaryocytic lineage (26;27), but are also intrinsically fated to differentiate along the
eosinophil lineage.
Overexpression of Gata1s in human fetal HSPCs induces eosinophilic hyperproliferation
To investigate the role of GATA1-isoforms in TL-associated eosinophilia, we examined
myeloid differentiation of human fetal CD34+-HSPCs ectopically expressing GATA1 or
GATA1s. We used a modified lentiviral LeGO-iG vector (30) to express simultaneously
murine Gata1s, or full length Gata1, and a shRNA directed to endogenous human GATA1
(LeGO-iG-Gata1/shG1 and LeGO-iG-Gata1s/shG1; Figure 3a). We achieved knock-down
of endogenous GATA1 mRNA to 30% of the original level and stable expression of Gata1
and Gata1s mRNA and protein, respectively (Figure 3b and Supplementary Figure 3). This
approach permitted investigation of the net effect of Gata1s in cells with a low level of
endogenous GATA1. As a control, we used the modified LeGO-iG vector to express non-
silencing shRNA (LeGO-iG-shSC; hereafter referred to as ‘empty vector control’).
Transduced cells were cultured in the same myeloid differentiation medium (containing G-
CSF, GM-CSF, IL3 and SCF), which supports differentiation of normal CD34+-HSPCs to
CD14+ monocytes and CD15+/CD16+ neutrophils (Figure 3c–d) (41), but supported
eosinophil differentiation of GATA1s-mutated TL-blasts (Figure 2b). Overexpression of
Gata1 or Gata1s induced formation of CD33mid/+ cells (Figure 3c) with highly granulated
cytoplasm (Figure 3d), resembling eosinophil precursors (compare to Supplementary Figure
2). Some of those contained abnormal coarse basophilic granules, reminiscent of pro-
eosinophilic granules found in AML FAB M4eo (Supplementary Figure 4). Expression of
Gata1s blocked differentiation to CD14+ monocytes and CD15+/CD16+ neutrophils to the
same extent as full length Gata1 (42–44) (Figure 3c). However, even though Gata1- and
Gata1s-transduced cells displayed a similar immunophenotype and morphology (Figure 3c–
d), only Gata1s-transduced eosinophil precursors were hyperproliferative in liquid culture in
an IL3-dependent manner, maintaining viability for more than 45 days (Figure 3e and
Supplementary Figure 5). In contrast, the proliferation rate of Gata1-transduced cells was
reduced (Figure 3e). Of note, the presence of an extra copy of chromosome 21 in trisomy 21
fetal HSPCs did not have a significant additional impact on the observed Gata1s phenotype
(Supplementary Figure 6).
Gata1s induces formation of atypical eosinophil colonies
In the methylcellulose- and collagen-based myeloid colony-forming unit (CFU) assay,
Gata1s increased the colony-forming capacity of transduced HSPCs (Figure 4a–b).
Importantly, Gata1s-, but not Gata1- or empty vector-transduced cells, gave rise to atypical
large myeloid colonies (Figure 4a and c). They were composed of eosinophil promyelocytes
(Figure 4di and Supplementary Figure 7; compare to Supplementary Figure 2) with
abnormal coarse pro-eosinophilic granules (compare to AML FAB M4eo in Supplementary
Figure 4a). The cells were similar to those seen in liquid culture of transduced HSPCs
(Figure 4di and 3d) or TL-blasts (Figure 2b). These atypical eosinophil colonies could be
replated without changing morphology (Figure 4e–f), such that after the fourth round of
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treplating, Gata1s-transduced cells had a 15-fold higher cumulative number of CFUs than
empty vector-transduced control cells. Histochemical staining of cells from the atypical
colonies were negative for toluidine blue (Figure 4g), alpha-naphtylacetate-esterase and
weakly positive for myeloperoxidase (Figure 4di–iii) excluding basophil, monocytic or
neutrophil lineage commitment, respectively. Many cells stained strongly positive for
polysaccharides (PAS-staining; Figure 4div), consistent with their high proliferative rates as
also indicated by the large number of metaphases (Figure 4dii–iv).
Chip cytometry and gene expression profiling confirm eosinophil lineage affiliation of
hyperproliferative Gata1s-transduced cells
To confirm that the Gata1s-transduced cells seen in the liquid cultures and CFU assays were
indeed eosinophil precursors, we performed chip cytometry and global gene expression
profiling.
High throughput chip cytometry (32), which allows more than 50 surface and intracellular
antigens to be measured in small number of cells, was used to comprehensively analyze the
immunophenotype of individual Gata1s-CFUs (Figure 4h–i). The cells exhibited bright
autofluorescence, characteristic for granulated eosinophils, intermediate expression of the
stem cell markers CD34 and CD90, and high levels of expression of the pan-leukocyte
antigen CD45, early myeloid antigen CD13 and IL-3 receptor (CD123) (Figure 4h). Low
CD117 expression excludes a mast cell origin of the hyperproliferative Gata1s-transduced
cells (Figure 4h–i). Expression of mature monocytic (CD14) and neutrophilic markers
(CD16) was low, consistent with the FACS data reflecting differentiation block imposed by
enforced Gata1s expression.
To determine the genetic program of Gata1s-, Gata1- and empty vector-transduced HSPCs
in an unbiased manner, we performed global gene expression profiling followed by GSEA
analysis (38). We used sets of genes, that are highly expressed (more than 2-fold,
PANOVA<0.05) in human monocytes, granulocytes, megakaryocytes, erythroid cells,
CD34+-HSPCs (S.E., J.H.K., unpublished data) compared to the other blood lineages. We
also included sets of genes specific for eosinophils, as compared to basophils and mast cells
(39;45). Using this approach, we first validated a significant (NOM p-val <0.05; FDR q-val
<0.25) upregulation of monocytic and granulocytic genes and downregulation of erythroid
and HSPC genes in the empty vector-transduced cells after four days of culture (Figure 5a
and Supplementary Figure 8).
As expected, ectopic Gata1-expression led to increased expression of eosinophil and
erythroid genes, while monocytic genes were reduced (Figure 5a and Supplementary Figure
9). In contrast, Gata1s-expression only caused an increase in the eosinophil gene set,
reaching significance after 14 days (NES: 2.73; P<0.001; q<0.001) (Figure 5a and
Supplementary Figures 10 and 11), while expression of monocytic, granulocytic, HSPC,
erythroid and, importantly, mast cell/basophil (45) gene sets were all reduced (Figure 5a,
Supplementary Figures 10–12). The results were validated by qRT-PCR analysis of
representative genes for each gene set (Figure 5b).
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tExpression of critical eosinophil genes, such as CLC and EPX, was markedly increased in
Gata1- and Gata1s-transduced cells (Figure 5b). To determine whether these genes are
regulated directly by GATA1/GATA1s, we performed chromatin-immunoprecipitation
followed by high throughput sequencing (ChIP-seq) in human GATA1s-mutated cell line
CMK stably expressing biotinylated GATA1 or GATA1s (J.X., S.H.O., J.H.K., unpublished
data). These analyses revealed that both GATA1 and GATA1s occupied promoter regions of
the eosinophil genes EPX and CLC comparably (Figure 5c).
Thus, Gata1s instructs an eosinophil expression program in hyperproliferative Gata1s-
transduced human fetal HSPCs (hereafter referred to as ‘Gata1s-eosinophil precursors’).
Eosinophil maturation is perturbed in Gata1s knockin mice
To evaluate the impact of Gata1s, expressed from its endogenous locus, on eosinophil
differentiation, we investigated a knockin murine embryonic stem cell (ESC) model
expressing the BirA enzyme (BirA) together with a biotinylated form of Gata1 (bioGata1) or
Gata1s (bioGata1s) (35). During eosinophil in vitro differentiation, we also observed the
hyperproliferation of Siglec-F+ eosinophils (46) only in bioGata1s-ESCs (Figure 6a–c).
However, the percentage of Siglec-F+/CCR+ mature eosinophils (47) was markedly reduced
(Figure 6c). Similarly, in the peripheral blood of Gata1Δe2-knockin mice (14), which
exclusively express Gata1s, Siglec-F+/CCR+ or SSChigh/Siglec-F+ mature eosinophils were
nearly absent (Figure 6d–e; for CBC see Supplementary Figure 13). However, the number of
Siglec-F+/CCR− or SSClow/Siglec-F+ eosinophil precursors was elevated (Figure 6d–e). The
accumulation of eosinophil precursors and the differentiation block was already evident in
the bone marrow of Gata1Δe2-knockin mice (Figure 6d–e).
Thus, the N-terminal domain of Gata1 plays a previously unprecedented role in eosinophil
development. Furthermore, these data exclude the possibility that the hyperproliferation of
human fetal HSPCs is due to ectopic expression of Gata1s from a lentiviral vector.
E2F-target genes are not repressed in Gata1s-eosinophil precursors
Next we assessed the expression of known E2F-bound target genes (48) in Gata1s-
transduced fetal HSPCs by microarray (Figure 7a; Supplementary Figure 14). GATA1, but
not GATA1s, represses the E2F transcription network by direct interaction with activating
E2F transcription factors (13;49). The E2F transcription network is activated in cycling cells
and repressed in terminally differentiating cells. As expected, E2F target genes were
downregulated during myeloid differentiation in the empty vector transduced cells
(Supplementary Figure 14a). Although ectopic expression of Gata1 perturbed myeloid
differentiation, it was associated with downregulation of E2F target genes (Supplementary
Figure 14b). In contrast, GATA1s failed to repress E2F target genes (Figure 7a,
Supplementary Figure 14c). This was confirmed by qRT-PCR analysis of several
representative genes from this gene set, including MYC, UNG and MCM5 (Figure 7b). The
relative upregulation of E2F targets MCM5 and MYC was also evident in sorted TL-
eosinophils (from three patients with eosinophilia) compared to eosinophils of a healthy
donor (Supplementary Figure 15).
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differentiation, leading to hyperproliferation of eosinophil precursors.
GATA1s occupancy at the MYC promoter is reduced
MYC is a direct target gene of E2F1. MYC is also a direct target of GATA1 and is repressed
by GATA1 during erythroid differentiation (10). To explore whether relative overexpression
of MYC in GATA1s-transduced cells is due to incomplete repression of an E2F1
transcription network or direct transcriptional regulation by GATA1s, we analyzed
occupancy of GATA1 and GATA1s at the MYC promoter by ChIP-seq analysis in CMK
cells stably expressing biotinylated GATA1 or GATA1s (Figure 7c). We identified one
distal (−900 to −600nt relative to MYC transcription start site [TSS]) and one proximal
(−100 to +100nt relative to MYC TSS) ChIP-seq peak for GATA1. Occupancy of GATA1s
was equal at the proximal region but modestly reduced at the distal region compared to that
of GATA1 (Figure 7c; for quantitative ChIP-PCR analysis see Figure 7d). The distal region
harbors three putative GATA1 binding sites (Supplementary Figure 16; ‘WGATAR motif’
(50;51). In contrast, the proximal peak contains only one putative GATA1 binding site
located around the peak summit. The flanking DNA sequences of each GATA motif are
different.
Reduced occupancy by GATA1s to the MYC promoter suggests that GATA1s may be less
potent in repressing MYC expression. To test this, we performed a transient reporter assay
using MYC promoter (P1 and P2 promoter) in CMK cells. While expression of GATA1
resulted in downregulation of luciferase reporter activity, GATA1s was unable to repress the
activity of MYC promoter in this assay (Figure 7e). Our data suggest a dual role of GATA1s
in the hyperproliferation of GATA1s-transduced promyelocytes. GATA1s fails to repress
E2F transcription network by direct interaction with E2F1 (13), leading to overexpression of
MYC; moreover, GATA1s is impaired in its capacity to repress MYC expression, most
likely due to impaired occupancy at the MYC promoter.
Knockdown of MYC or DP1 reverts the GATA1s-hyperproliferative phenotype of eosinophil
promyelocytes
To test the hypothesis that the hyperproliferative phenotype associated with GATA1s is due
to incomplete repression of an E2F transcription network and MYC, we performed a rescue
experiment. MYC or DP1, an obligate E2F partner, were downregulated by an shRNA-
approach and GATA1s expression in human fetal HSPCs was enforced simultaneously
(Supplementary Figure 17a). Reduction of MYC (40% compared to control) or DP1 (60%
compared to control; see Supplementary Figure 17b–c) was associated with the formation of
significantly fewer colonies in collagen-based CFU assays (Figure 8a). In methocellulose-
based CFU assays, DP1 knockdown led to a reduced number of total CFUs (Figure 8b). Of
note, downregulation of either MYC or DP1 significantly decreased the formation of
atypical eosinophil colonies (Figure 8c). In the case of MYC knockdown, these colonies
were not only less abundant, but also smaller in size (Supplementary Figure 17d). In liquid
culture, the proliferation was reduced upon DP1 or MYC knockdown, but the monocytic/
neutrophilic differentiation block was retained (Figure 8d Supplementary Figure 17e).
Moreover, treatment of Gata1s-eosinophil precursors with JQ1 led to marked dose-
Maroz et al. Page 9
Leukemia. Author manuscript; available in PMC 2014 December 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tdependent decrease of viable cells (Figure 8e). JQ1 is a BRD4 inhibitor that was shown to
selectively reduce MYC expression (52).
These findings provide evidence that incomplete repression of the E2F transcription
network, particularly the E2F and GATA1 target gene MYC, accounts in large measure for
the hyperproliferative phenotype associated with GATA1s.
Discussion
Here we report that eosinophils are derived from a TL cell clone in a substantial fraction of
DS patients with TL. TL-blasts display an expression program characteristic of eosinophils
and can differentiate along the eosinophil lineage, even in the absence of documented
eosinophilia. TL is consistently associated with N-terminal truncating GATA1-mutations
(GATA1s) and the eosinophils in TL with eosinophilia harbor N-terminal truncating GATA1
mutations. This suggests that GATA1s plays an instructive role, which drives an intrinsic
propensity of TL-blasts to differentiate along the eosinophil lineage. In fact we demonstrated
that, as with wild-type GATA1, GATA1s promoted differentiation of fetal hematopoietic
progenitors along the eosinophil lineage through occupancy and transactivation of
eosinophil genes. Since GATA1s was unable to repress a subset of GATA1 target genes,
most notably MYC and the pro-proliferative E2F transcription network, the balance between
cell differentiation and proliferation is perturbed in the presence of GATA1s (Figure 8f),
leading to hyperproliferation of eosinophil precursors. Strikingly, the accumulation of
eosinophil precursors and the block in terminal eosinophil differentiation were also evident
in Gata1s-knockin mouse ESCs and Gata1Δe2 mice in vivo.
Previously, we and others demonstrated that GATA1 serves as a molecular brake to restrict
proliferation of megakaryocytic and erythroid progenitors through repression of E2F target
genes (13;49). The repression is mediated in part by direct protein interaction with E2Fs
(13;49). This function of GATA1 is impaired in GATA1s. Our study suggests that this
function of GATA1 extends to eosinophil precursors and is not restricted to the
megakaryocytic and erythroid lineages. The central role of E2F in GATA1s-induced
hyperproliferation of eosinophilic precursors is underscored by abrogation of this phenotype
upon knockdown of the essential E2F interaction partner DP1. Importantly, we also
identified MYC, a direct target gene of E2Fs and GATA1 (10;53), as an effector of
GATA1s-mediated transformation. MYC activates the E2F transcription network either
directly (54) or indirectly (55). Here we demonstrated that the occupancy of GATA1s at the
MYC promoter is reduced. It remains unclear whether the presence of multiple putative
GATA1 binding sites, the DNA sequence flanking the GATA1 motif and/or the failure to
interact with bound cofactors contribute to the differential binding affinity of GATA1 and
GATA1s to this genomic region. However, our results suggest a model in which GATA1s is
defective in repressing MYC expression through impaired promoter association, leading to
perturbation of the MYC-E2F loop in TL eosinophil precursors. Whether pharmacologic
inhibition of MYC using JQ1 might also be a therapeutic option in DS-AMKL or clinically
relevant TL, warrants consideration.
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unrestricted proliferation of leukemic blasts through incomplete repression of MYC and the
E2F transcription network. On the other hand, GATA1s transactivates an eosinophil
expression program, thereby promoting the differentiation of the TL-blasts into this lineage.
We demonstrated that at least in some instances of TL, eosinophilia is intrinsic to the
leukemic clone, as the same mutation in GATA1 is present in both eosinophils and
megakaryoblasts. Eosinophilia may have been overlooked previously in TL either because
eosinophil counts were performed only at initial diagnosis, before blasts differentiated, or, in
other cases, the mutant GATA1 clone is small thereby masking the enhanced eosinophil
differentiation. Similarly, the accumulation of eosinophil precursors and the blocked
terminal eosinophil differentiation in Gata1Δe2 mice was previously unrecognized. Thus,
Gata1Δe2 mice may represent a useful tool to study eosinophilopoiesis and the role of
eosinophils in allergic responses in vivo. It would also be interesting to investigate whether
individuals with inherited GATA1s-mutations without trisomy 21 (56) have defective
eosinophilopoiesis.
Miyauchi et al. (26) also demonstrated differentiation of TL megakaryoblasts into
granulocytic cells with coarse basophilic granules. Based on electron microscopy, they
described a hybrid basophilic/mast cell nature of the cells. Suda et al. (27) and Worth et al.
(57) also reported infants that developed TL with extreme basophilia. Basophils and
eosinophils share common surface antigens (CCR3, IL3R, IL5R, CD116) and some granule
proteins (CLC, HDC) (45). Although distinct progenitors of mast cells, basophils and
eosinophils have been identified, these cells share many features (58). The Gata1/Gata1s-
derived eosinophil precursors and TL-eosinophils contained eosinophilic and coarse
basophilic (pro-eosinophilic) granules. These pro-eosinophilic granules are otherwise only
described in MDS and AML FAB M4eo. The observed eosinophilia and basophilia suggest
that TL-blasts may give rise to both lineages. However, due to their abnormal coarse
basophilic granules, the eosinophil precursors may also be misinterpreted as basophils. Our
comprehensive evaluation of Gata1s-transduced hyperproliferative progenitors, however,
clearly supports the eosinophil over other lineages.
In conclusion, our work provides novel insight into molecular mechanisms underlying TL
and associated clonal eosinophilia. Our findings illustrate the pleiotropic effects of GATA1
in the hematopoietic system in a GATA1-associated hematologic disorder. Moreover, our
observations have clinical implications. We propose that in addition to TL patients, the
status of GATA1 should also be assessed in all DS neonates that present with abnormal
eosinophils in blood. Such patients should be monitored for the development of subsequent
DS-AKML.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Abnormal eosinophils in a fraction of TL patients
(a) Diagram showing the absolute eosinophil count (AEC; normal: less than 600 ×106/L)
and relative eosinophil count (REC; normal: less than 4%) in n=70 DS neonates with TL as
assessed by morphological examination of blood smears. (b) TL eosinophils (arrowhead)
and a TL-blast (arrow) with eosinophilic granulation (MGG-staining; 1000× original
magnification). (c) Microscopic images (left panel; MGG-staining; 1000× original
magnification) and sequencing (right panel) of sorted CD15+/CD16+ TL-eosinophils and
CD34+/CD41+/low blasts (n=4). The mutated regions are highlighted in red (duplication,
insertion and point mutations) and blue (deletion). Patient #1 and #2 are male (GATA1
hemizygous), while #3 and #4 are female (GATA1 heterozygous).
All photomicrographs were taken using an Olympus BX41 Microscope.
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tFigure 2. TL-blasts express an eosinophil program and can differentiate into eosinophils
(a) GSEA of eosinophil genes (39) in sorted TL-blasts (n=6) compared to non-DS AMKL
(n=5). (b) Microscopic images (MGG-staining, 1000× original magnification) of CD34+
cells (left) and TL-blasts (right; n=3) of DS patients on day 0 and on day 11 of culture in
myeloid (SCF/ IL3/ G-CSF/ GM-CSF) differentiation medium. (c) Expression of eosinophil
and basophil genes in undifferentiated (day 0) and differentiated TL-blasts (day 11) as well
as HSPCs measured by qRT-PCR (n=3; mean±SD). B2M expression was used as an
endogenous control. (d) Microscopic images (toluidine blue staining, 1000× original
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tmagnification) of TL-blasts of one representative patient on day 11 of culture in myeloid
differentiation medium. Normal blood basophils were used as a positive staining control
(left).
Photomicrographs were taken with a Keyence Biorevo BZ-9000 microscope and processed
with the BZ-II viewer software.
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tFigure 3. Overexpression of GATA1s perturbs normal myeloid differentiation of human fetal
CD34+-HSPCs
(a) Schematic illustration of the LeGO-iG-shSC (ctr), LeGO-iG-Gata1/shG1 (Gata1) and
LeGO-iG-Gata1s/shG1 (Gata1s) vectors (30). (b) qRT-PCR of mouse Gata1 and human
GATA1 using specific primers in LeGO-iG-shSC (ctr)-, LeGO-iG-Gata1/shG1 (Gata1/
shG1)- and LeGO-iG-Gata1s/shG1 (Gata1s/shG1)-transduced fetal CD34+-HSPCs (mean
±SD of replicates; *PANOVA<0.05 compared to ctr). (c) FACS analysis of Gata1-, Gata1s-
and empty vector control (ctr)-transduced HSPCs grown for 14 days in myeloid
differentiation medium. Representative dot plots of n=4 independent experiments are
presented. (d) MGG staining of empty vector, Gata1- and Gata1s-transduced cells on day 14
of myeloid differentiation culture (1000× original magnification). Photomicrographs were
taken with a Keyence Biorevo BZ-9000 microscope and processed with the BZ-II viewer
Maroz et al. Page 19
Leukemia. Author manuscript; available in PMC 2014 December 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tsoftware. (e) Number of Gata1-, Gata1s- and empty vector control (ctr)-transduced fetal
HSPCs grown in myeloid differentiation medium relative to the control. Data from n=4
independent experiments are presented as mean±SD. **PANOVA<0.01 compared to ctr.
Maroz et al. Page 20
Leukemia. Author manuscript; available in PMC 2014 December 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tFigure 4. Gata1s induces the proliferation of eosinophil precursors
(a) Number of CFUs per 500 Gata1-, Gata1s- and empty vector control (ctr)-transduced
fetal CD34+-HSPCs. Replicates from n=4 independent experiments are presented as mean
±SD. (*PANOVA<0.05 of the total CFU count compared to ctr). (b) Photograph (1× original
magnification) of collagen-based colony-forming assays of Gata1-, Gata1s- and empty
vector control (ctr)-transduced fetal CD34+-HSPCs. (c) Microscopic images (phase contrast,
50× original magnification) of a control CFU-G (top) and atypical Gata1s-CFUs (bottom).
(d) Microscopic images of cells from an individual picked atypical Gata1s-CFU (1000×
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toriginal magnification). (i) MGG-staining; (ii) esterase staining (EST); (iii) myeloperoxidase
staining (MPO); (iv) periodic acid-Shiff staining (PAS). (e) Replating capacity of Gata1s-
CFUs calculated as the cumulative CFU count per each round of replating compared to the
Gata1- and empty vector-transduced HSPCs (***PANOVA<0.001 compared to ctr). (f)
Morphology (MGG-staining; 1000× original magnification) of Gata1s-transduced HSPCs
after the third round of replating. (g) Toluidine blue staining of Gata1s-transduced cells
from a picked CFU (1000× original magnification). Peripheral blood basophils (bottom)
were used as a positive control. (h–i) Expression of surface and intracellular markers of
Gata1s-transduced cells from an individual picked Gata1s-CFU measured by chip
cytometry. A clustered heatmap of transformed fluorescence intensity data (h) and raw
image data (j) are presented.
Photomicrographs were taken with an Olympus BX41 Microscope and processed with
AnalySIS software (Olympus Corporation).
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tFigure 5. Expression of lineage markers and genes in Gata1-/ Gata1s-transduced HSPCs
(a) Heatmap of the normalized enrichment score (NES) obtained by GSEA of Gata1-,
Gata1s- and empty vector control (ctr)-transduced fetal HSPCs grown 4 days (and 14 days)
in myeloid differentiation medium compared to empty vector control (ctr)-transduced cells
on day 0 (n=2). Gene sets specific (more than 2-fold, PANOVA<0.05) for human monocytes,
granulocytes, megakaryocytes, erythroid cells and CD34+-HSPCs (Emmrich and Klusmann,
unpublished data), and specific for eosinophils and mast cells (39) were used. The
corresponding enrichment plots and statistics are presented in Supplementary Figures 8–11.
(b) The expression of key erythroid, monocytic, eosinophil and basophil genes was validated
by qRT-PCR in replicates from another independent experiment (mean±SD of replicates;
*PANOVA<0.05, **PANOVA<0.01, ***PANOVA<0.001 compared to ctr). (c) ChIP-seq
density plots of Gata1 (blue) and Gata1s (red) enrichment on promoter regions of eosinophil
genes EPX and CLC.
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tFigure 6. Gata1s perturbs eosinophilopoiesis in mice
(a) Schematic illustration of the eosinophil ESC differentiation protocol. (b) Number
of bioGata1-, bioGata1s- and BirA control murine ESCs grown in eosinophil differentiation
medium relative to day 0. Data from n=3 independent experiments are presented as mean
±SD. (c) FACS analysis on day 20 of eosinophil ESC differentiation. Mean±SD of n=3
independent experiments is indicated. (d–e) FACS analysis for eosinophils in peripheral
blood and bone marrow of WT and Gata1Δe2-mice (14). (d) FACS-plots and mean±SEM.
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t(e) Diagrams and statistics for the indicated populations in the peripheral blood (left) and
bone marrow (right).
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tFigure 7. Gata1s fails to repress E2F target genes in eosinophilic precursors
(a) GSEAs of E2F target genes previously identified by ChIP-chip analysis (48) in Gata1-,
Gata1s- and empty vector control (ctr)-transduced fetal HSPCs grown for 4 days in the
myeloid differentiation medium: Gata1s vs. ctr (left), Gata1s vs. Gata1 (middle) and Gata1
vs. ctr (right). Enrichment plots (top) and statistics (table below) are provided. (b) qRT-PCR
of key E2F target genes in Gata1-, Gata1s- and empty vector control (ctr)-transduced fetal
HSPCs grown for 7 days in the myeloid differentiation medium from another independent
experiment (mean±SD of replicates; *PANOVA<0.05, **PANOVA<0.01, ***PANOVA<0.001
compared to ctr). (c) ChIP-seq density plots of Gata1 and Gata1s on MYC genomic region
and (d) ChIP followed by qRT-PCR (mean±SD of replicates; *PANOVA<0.05,
**PANOVA<0.01, ***PANOVA<0.001 compared to ctr). The PCR amplicon is shown as
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tgreen bar in Figure 7c. (e) Luciferase reporter assay using the MYC promoter in GATA1/
GATA1s transfected CMK cells. pGL4.1 was used as a negative control (mean relative
luminescence unit±SD of n=2 independent experiments; *PANOVA<0.05, **PANOVA<0.01,
***PANOVA<0.001 compared to empty vector ctr).
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tFigure 8. Knockdown of either MYC or DP1 partially rescues GATA1s-induced
hyperproliferative phenotype of eosinophil precursor cells
(a) Photograph (1× original magnification) of collagen-based colony-forming assays of an
empty vector control (ctr), Gata1-, Gata1s-, shMYC/Gata1s and shDP1/Gata1s-transduced
fetal CD34+-HSPCs. Number of CFUs (b) and atypical eosinophilic CFUs (c) per 500 empty
vector (ctr), Gata1-, Gata1s-, shMYC/Gata1s and shDP1/Gata1s-transduced fetal CD34+-
HSPCs. Replicates from n=2 independent experiments are presented as mean±SD
(*PANOVA<0.05 of the total CFU count compared to ctr). (d) Number of empty vector
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tcontrol (ctr), Gata1-, Gata1s-, shMYC/Gata1s and shDP1/Gata1s -transduced fetal CD34+-
HSPCs grown in myeloid differentiation medium relative to day 0. Data from n=2
independent experiments are presented as mean±SD. ****PANOVA<0.0001 compared to
Gata1s. (e) Number of Gata1s-eosinophil precursors (after 20 days of culture) treated with
MYC inhibitor JQ1 (52) relative to the untreated control. Data from n=2 independent
experiments are presented as mean±SD. ****PANOVA<0.0001. (f) Model of GATA1s-
mediated proliferation of eosinophil progenitors. Both GATA1 and GATA1s bind promoters
of eosinophil genes therefore activate eosinophil differentiation program. GATA1 represses
E2F transcription network and transcription of MYC, therefore works as “molecular brake”
to restrict proliferation of eosinophil progenitor cells. GATA1s fails to repress E2F
transcription network and MYC and thus causes hyperproliferation of eosinophil progenitors
in DS-TL patients.
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